Rapid determination on resistance of ofloxacin for Mycobacterium tuberculosis with microplate alamar blue assay
ZHENG Yu-hong1, 2, GUO Qian1, 2, 3, LI Chao1, 2, 4, WEI Jian-hao1, 2, 4, ZHAO Li-li1, 2, JIANG Yi1, 2, ZHAO Xiu-qin1, 2, WAN Kang-lin1, 2, LI Gui-lian1, 2
1.State Key Laboratory for Infectious Disease Prevention and Control, National Institute for CommunicableDisease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; 2.Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou 310003, China; 3.Pathogenic Biology Institute, South of China University, Hengyang 421000, China; 4.Wenzhou Medical College, Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou 325035, China
Abstract:We assessed the feasibility of microplate alamar blue assay for determining the ofloxacin resistance of Mycobacterium tuberculosis (M. tuberculosis). MIC of ofloxacin of 78 M. tuberculosis isolates was determined by microplate alamar blue assay and the time of obtaining the results was recorded; receiver operating characteristic (ROC) curve was used to determine the resistant threshold value of ofloxacin, and compared to the conventional proportional method. Results showed that the resistant threshold value of ofloxacin was 2 μg/mL for microplate alamar blue assay, and compared to the gold standard proportional method, the sensitivity and specificity were 88.6% and 94.1%, respectively. And the time obtaining the results for microplate alamar blue assay was 8 days. Microplate alamar blue assay is simple, sensitive and rapid, and is a promising alternative method for rapidly determining the resistance of ofloxacin of M. tuberculosis.
[1] World Health Organization. Anti-tuberculosis drug resistance in the world: fourth global report, WHO/HTM/TB/2008.394[R]. Geneva: World Health Organization, 2008. [2] Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China[J]. N Engl J Med, 2012, 366(23): 2161-2170. doi:10.1056/NEJMoa1108789 [3] Mokrousov I, Jiao WW, Sun GZ, et al. Evolution of drug resistance in different sublineages of Mycobacterium tuberculosis Beijing genotype[J]. Antimicrob Agents Chemother, 2006, 50(8): 2820-2823. doi:10.1128/AAC.00324-06 [4] Takiff H, Guerrero E. Current prospects for the fluoroquinolones as first-line tuberculosis therapy[J]. Antimicrob Agents Chemother, 2011, 55(12): 5421-5429. doi:10.1128/AAC.00695-11 [5] Wells WA, Boehme CC, Cobelens FG, et al. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action[J]. Lancet Infect Dis, 2013, 13(5): 449-458. doi:10.1016/S1473-3099(13)70025-2 [6] Li GL, Zhang JR, Zhao XQ, et al. Rapid detection on resistant of rifampicin and isoniazid for Mycobacterium tuberculosis clinical isolates by Alamar Blue asssay[J]. Chin J Zoonoses, 2012, 28(4): 319-326. (in Chinese) 李桂莲, 张敬蕊, 赵秀芹, 等. 微孔板Alamar blue显色法检测结核分枝杆菌利福平和异烟肼耐药性的研究[J]. 中国人兽共患病学报, 2012, 28(4): 319-322. [7] Martin A, Morcillo N, Lemus D, et al. Multicenter study of MTT and resazurin assays for testing susceptibility to first-line anti-tuberculosis drugs[J]. Int J Tuberc Lung Dis, 2005, 9(8): 901-906. [8] Chauca JA, Palomino JC, Guerra H. Evaluation of the accuracy of the microplate Alamar Blue assay for rapid detection of MDR-TB in Peru[J]. Int J Tuberc Lung Dis, 2007, 11(7): 820-822. [9] Leonard B, Coronel J, Siedner M, et al. Inter- and intra-assay reproducibility of microplate Alamar blue assay results for isoniazid, rifampicin, ethambutol, streptomycin, ciprofloxacin, and capreomycin drug susceptibility testing of Mycobacterium tuberculosis [J]. J Clin Microbiol, 2008, 46(10): 3526-3529. doi:10.1128/JCM.02083-07 [10] Laszlo A, Rahman M, Espinal M, et al. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998[J]. Int J Tuberc Lung Dis, 2002, 6(9): 748-756. [11] Basic professional committee, Chinese antituberculosis association. Rules for the inspection of the laboratory diagnosis of tuberculosis[M]. Beijing: China Education and Culture Publishing House, 2006: 52. (in Chinese) 中国防痨协会基础专业委员会. 结核病诊断实验室检验规程[M]. 北京:中国教育文化出版社,2006:52. [12] WHO. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs (WHO/HTM/TB/2008.392)[M]. Geneva: World Health Organization, 2008:11. [13] World Health Organization. Global tuberculosis report 2013[R]. Geneva, Switzerland: World Health Organization, 2013: 45-58. [14] Wang Z, Cui ZL, Ma XL, et al. Evaluation of the application of trace MIC on the examination of drug sensitivity of Mycobacterium tuberculosis [J]. Mod Prevent Med, 2014, 141(8): 1487-1489. (in Chinese) 王芝, 崔振玲, 马晓莉, et al. 微量MIC检测结核分枝杆菌药物敏感性的应用评价研究[J]. 现代预防医学, 2014, 41(8): 1487-1489. [15] Jiang J, Zhang J, Zhang H, et al. The practical evaluation of second-line anti-tuberculosis drug sesceptibility test using MGIT 960 system[J]. Chin J Antituberc, 2012, 34(8): 527-531. (in Chinese) 蒋俊, 张娟, 张红, et al. MGIT960系统行二线抗结核药物敏感性试验的实用性评价[J]. 中国防痨杂志, 2012, 38(8): 527-531. [16] Chen ZN, Zhao LL, Yi SL, et al. Clinical trial of BACTEC MGIT 960 for drug susceptibility testing on Mycobacterium tuberculosis [J]. Chin J Zoonoses, 2013, 29(2): 166-169. (in Chinese) 陈忠南, 赵丽丽, 易松林, 等. BACTEC MGIT960在结核分枝杆菌药物敏感性试验中的临床研究[J]. 中国人兽共患病学报, 2013, 29(2): 166-169.